Design of a Transdermal Sustained Release Formulation Based on Water-Soluble Ointment Incorporating Tulobuterol Nanoparticles.
endocytosis
nanoparticle
ointment
transdermal delivery system
tulobuterol
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
10 Nov 2022
10 Nov 2022
Historique:
received:
14
10
2022
revised:
08
11
2022
accepted:
08
11
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
We aimed to investigate which base was suitable for preparing transdermal formulations incorporating tulobuterol (TUL) nanoparticles (30-180 nm) in this study. Three bases (water-soluble, absorptive, and aqueous ionic cream) were selected to prepare the transdermal formulations, and TUL nanoparticles were prepared with a bead-milling treatment. In the drug release study, the TUL release from the water-soluble ointment was higher than that from the other two ointments. Moreover, the addition of
Identifiants
pubmed: 36365248
pii: pharmaceutics14112431
doi: 10.3390/pharmaceutics14112431
pmc: PMC9697680
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the Ministry of Education, Culture, Sports, Science, and Technology of Japan
ID : 21K06656
Références
J Pharm Sci. 1997 Dec;86(12):1369-73
pubmed: 9423148
Drug Deliv. 2016;23(2):564-78
pubmed: 25006687
Int J Mol Sci. 2021 May 12;22(10):
pubmed: 34066280
Int J Nanomedicine. 2019 Feb 18;14:1213-1227
pubmed: 30863055
Curr Pharm Des. 2020;26(27):3203-3217
pubmed: 32452322
Pharmaceutics. 2021 Sep 08;13(9):
pubmed: 34575501
Biochem J. 2008 Jun 15;412(3):415-23
pubmed: 18498251
Toxicology. 2014 May 7;319:53-62
pubmed: 24598350
Allergol Int. 2013 Mar;62(1):37-43
pubmed: 23000726
Biochim Biophys Acta. 2012 Mar;1818(3):502-11
pubmed: 22155257
Pharmaceutics. 2015 Oct 22;7(4):438-70
pubmed: 26506371
Biol Pharm Bull. 2014;37(1):96-104
pubmed: 24389486
Dokl Biol Sci. 2014 Nov;459:330-3
pubmed: 25560208
J Control Release. 2019 May 10;301:140-145
pubmed: 30876952
Adv Drug Deliv Rev. 2004 Mar 27;56(5):603-18
pubmed: 15019749
Adv Drug Deliv Rev. 2019 Apr;144:90-111
pubmed: 31419450
Adv Mater. 2009;21:419-424
pubmed: 19606281
Regul Toxicol Pharmacol. 2021 Feb;119:104836
pubmed: 33249100
Int J Nanomedicine. 2021 Aug 10;16:5343-5356
pubmed: 34413642
Int J Nanomedicine. 2018 Sep 06;13:5215-5229
pubmed: 30233182
Drug Dev Ind Pharm. 2016;42(6):845
pubmed: 27031915
Annu Rev Immunol. 1999;17:593-623
pubmed: 10358769
Int J Mol Sci. 2020 Sep 25;21(19):
pubmed: 32992931
Biol Pharm Bull. 2019 Apr 1;42(4):586-593
pubmed: 30686806
Drug Deliv Transl Res. 2017 Feb;7(1):53-65
pubmed: 27672079
Curr Pharm Des. 2021;27(42):4315-4329
pubmed: 34779364
Small. 2011 Jul 18;7(14):1919-31
pubmed: 21695781
Int J Mol Sci. 2019 Jul 25;20(15):
pubmed: 31349657
Nanoscale. 2012 Mar 21;4(6):1881-94
pubmed: 22334401
Arzneimittelforschung. 2004;54(5):280-5
pubmed: 15212190
Pharm Dev Technol. 2011 Oct;16(5):497-510
pubmed: 20550465
Antiviral Res. 2021 Nov;195:105191
pubmed: 34678331
Adv Drug Deliv Rev. 2018 Mar 1;127:35-45
pubmed: 28867296
J Pharm Sci. 1997 Dec;86(12):1394-9
pubmed: 9423153
Molecules. 2016 Dec 15;21(12):
pubmed: 27983701
Int J Clin Pharmacol Ther. 2018 Aug;56(8):381-386
pubmed: 29932416
Biol Pharm Bull. 2015;38(12):1918-24
pubmed: 26632183